Replies to post #223139 on Amarin Corp Plc (AMRN)

[HDGabor]

M-

Do we have enough diabetics in the US to add a few more million patients to the population?

The 20 million annualized (statin) patients include diabetics … includes everybody who is on statin.

Best,
G

[Optionsrbest4u]

No, those 15 million peak Vascepa recipeints are quite reasonable 'IF' the label is appropriate for the benefit. We of course won't know for awhile; obviously Vascepa must get a label for preventive.

Does it really make sense to say 'yeah, you are high risk...but you have never had a cardio event' so no Vascepa for you? Then a few months later it is 'Oh wow...now you have had a heart attack/stroke and by all means you need to be on Vascepa - just wish we had put you on it a month ago'!!

Physicians aren't stupid and neither are consumers...once they realize the benefit (DTC advertising) they will be demanding to get a Vascepa RX; and if they have to eat 4 bags of potato chips before having a lipid panel so they can first get on statins, they will do it.

[jessellivermore]

I have a tremendous amount of respect for G ..As business man and as a source for so much material Amarin...He has been a big help for all the years he has posted on this MB..

On the other hand, I think he has a narrow focus when it comes to the science and medicine...When I say narrow focus I actually mean he fails to appreciate the full potential of Vascepa EPA...

When I think of V..I do not think plaques or even necessarily CVD events..But rather that EPA effects every cell in the body except Red blood cell which may as one poster suggested be simply carriers of EPA..I do not think of statins..I don't know what statins really do and have never heard a comprehensive explanation as to their MOA...By process of elimination I imagine they reduce inflammation in the arterial blood vessels..Nothing else makes sense to me...

I have a very good understanding of how EPA works...Perhaps not every aspect but enough to understand therapeutic doses of EPA will change clinical medicine profoundly..Because EPA has the same effects on neural cells, cells in the GI tract, The lungs, the muscles, the connective tissue, the kidneys and even the cells of the inflammatory and immune
systems..Because they all have COX, LOX and PPAR receptors..Not just the Cardio vascular system...

The arguments predicting sales of V in this and other countries is no more accurate than picking winners at Churchill Downs..

Another problem on the board is a misunderstanding of the power of the label...Clinicians are not bound by label indications...And the majority will prescribe what they think is therapeutic and not unsafe...There will always be the timid, unimaginative and those bounded by authority..But the majority of clinicians will make their own decisions..And IMO statins will not be a very important issue to many of them...I also do not think insurance will be a huge impediment in the long run..And I say that as someone who is currently paying Tier 4 prices for V..The reason I pay Tier 4 for V is that V is currently only indicated for trigs over 500 mg/dk to lower the risk of Acute Pancreatitis...And there are other drug ie. Generic Lovaza that lowers trigs more effectively than V...If V is being used therapeutically for conditions not treated successfully by other drugs...The Tier 4 rule does not apply..

Vascepa is going to be a game changer and not just in CVD..I am very optimistic V will be able to retard the development of Alzheimers' As optimistic as I was back in 2010 that EPA would be therapeutic in Cardiovascular disease..I am also convince EPA will show benefits in many other degenerative associated with aging....

":>) JL